BR112022005226A2 - Carboxilatos bicíclicos como moduladores de tranportadores e usos dos mesmos - Google Patents

Carboxilatos bicíclicos como moduladores de tranportadores e usos dos mesmos

Info

Publication number
BR112022005226A2
BR112022005226A2 BR112022005226A BR112022005226A BR112022005226A2 BR 112022005226 A2 BR112022005226 A2 BR 112022005226A2 BR 112022005226 A BR112022005226 A BR 112022005226A BR 112022005226 A BR112022005226 A BR 112022005226A BR 112022005226 A2 BR112022005226 A2 BR 112022005226A2
Authority
BR
Brazil
Prior art keywords
modulators
bicyclic
treatment
carboxylates
compounds
Prior art date
Application number
BR112022005226A
Other languages
English (en)
Inventor
Gregory Goreczny
Vincent Sandanayaka
Original Assignee
Nirogy Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nirogy Therapeutics Inc filed Critical Nirogy Therapeutics Inc
Publication of BR112022005226A2 publication Critical patent/BR112022005226A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

carboxilatos bicíclicos como moduladores de tranportadores e usos dos mesmos. a presente invenção em geral se refere ao campo de moduladores de transportador, por exemplo, inibidores de transportador de monocarboxilato, e mais particularmente aos novos compostos de carboxilato enona bicíclicos, a síntese e uso destes compostos e suas composições farmacêuticas, por exemplo, no tratamento, modulação e/ou prevenção de condições fisiológicas associadas com a atividade de transportador de monocarboxilato tal como no tratamento de câncer e outros distúrbios neoplásticos, rejeição de transplante de tecido ou órgão.
BR112022005226A 2019-09-25 2020-09-24 Carboxilatos bicíclicos como moduladores de tranportadores e usos dos mesmos BR112022005226A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962905606P 2019-09-25 2019-09-25
PCT/US2020/052413 WO2021061929A1 (en) 2019-09-25 2020-09-24 Bicyclic carboxylates as modulators of transporters and uses thereof

Publications (1)

Publication Number Publication Date
BR112022005226A2 true BR112022005226A2 (pt) 2022-06-14

Family

ID=75166130

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005226A BR112022005226A2 (pt) 2019-09-25 2020-09-24 Carboxilatos bicíclicos como moduladores de tranportadores e usos dos mesmos

Country Status (13)

Country Link
US (1) US20220281888A1 (pt)
EP (1) EP4034112A4 (pt)
JP (1) JP2022550314A (pt)
KR (1) KR20220101078A (pt)
CN (1) CN114615980A (pt)
AU (1) AU2020356491A1 (pt)
BR (1) BR112022005226A2 (pt)
CA (1) CA3149987A1 (pt)
IL (1) IL290990A (pt)
MX (1) MX2022003611A (pt)
TW (1) TW202126661A (pt)
WO (1) WO2021061929A1 (pt)
ZA (1) ZA202202619B (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
WO2013109972A2 (en) * 2012-01-20 2013-07-25 Regents Of The University Of Minnesota Therapeutic compounds
US20160115146A1 (en) * 2013-06-07 2016-04-28 Universite Catholique De Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
WO2016081464A1 (en) * 2014-11-17 2016-05-26 Nirogyone Therapeutics, Inc. Monocarboxylate transport modulators and uses thereof
CA2974697A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Pyrimidine-2,4-(1h,3h)-dione derivatives and pharmaceutical compositions thereof and their use as inhibitors of monocarboxylate transporters
SG11202009586WA (en) * 2018-03-30 2020-10-29 Nirogy Therapeutics Inc Bicyclic enone carboxylates as modulators of transporters and uses thereof

Also Published As

Publication number Publication date
US20220281888A1 (en) 2022-09-08
CA3149987A1 (en) 2021-04-01
AU2020356491A1 (en) 2022-03-31
ZA202202619B (en) 2023-12-20
KR20220101078A (ko) 2022-07-19
EP4034112A1 (en) 2022-08-03
JP2022550314A (ja) 2022-12-01
MX2022003611A (es) 2022-04-20
IL290990A (en) 2022-05-01
TW202126661A (zh) 2021-07-16
WO2021061929A1 (en) 2021-04-01
CN114615980A (zh) 2022-06-10
EP4034112A4 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
CR20220312A (es) Compuestos tricíclicos sustituidos
MX2021012549A (es) Derivados de tetrahidro-1h-ciclopenta[cd]indeno como inhibidores del factor inducible por hipoxia-2(alfa).
CR20220363A (es) Compuestos tricíclicos sustituidos
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MY165624A (en) N-acylsulfonamide apoptosis promoters
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
AU2016213805A1 (en) Nuclear transport modulators and uses thereof
BR112015022263A2 (pt) N-acil-n’-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas, seus usos, e composição farmacêutica
EA201692010A1 (ru) Фармацевтическое соединение
EA201490407A1 (ru) Содержащие гидразид модуляторы нуклеарного транспорта и их применения
PH12016500225A1 (en) Novel quinoline-substituted compound
BR112014031730A2 (pt) entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1
GEP20166484B (en) Protein kinase inhibitors
MX2022007155A (es) Derivados de cromano novedosos que tienen actividad de degradacion de receptor de estrogeno y usos de los mismos.
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
CR20210127A (es) Molécula de unión al antigeno anti grupo de diferenciación 137 (cd137) y su uso
MX2022014925A (es) Moduladores de il-17a.
MX2022014924A (es) Moduladores de il-17a.
EA201790070A1 (ru) Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70
ZA202005803B (en) Bicyclic enone carboxylates as modulators of transporters and uses thereof
MX2022012739A (es) Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.
BR112022000505A8 (pt) Compostos de 3,4-(anel fundido em 5)-5-fenil-pirrolidin-2-ona n-substituídos como inibidores de enzima isoqc e/ou qc
BR112022005226A2 (pt) Carboxilatos bicíclicos como moduladores de tranportadores e usos dos mesmos
UA107349C2 (en) Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]